Key Takeaways Novo Nordisk cut its 2025 outlook as Wegovy and Ozempic face slower uptake and rising competition.CagriSema hit key weight loss goals in late-stage studies, with a regulatory filing planned for 2026.Novo Nordisk is also advancing cagrilintide, Amycretin, and adding assets via acquisitions and licensing.Novo Nordisk (NVO) has achieved tremendous commercial success with its blockbuster semaglutide products, Wegovy (for obesity) and Ozempic (for diabetes). However, the company’s growth trajectory ...